Table 3 Multivariate analysis for all-cause mortality.

From: Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3–5

Model

Variable

p valuea

SHR

CI 95%

Crude model

OPG

 < 0.001

1.10

1.06–1.14

Model 1

OPG

 < 0.001

1.08

1.05–1.12

Age

0.079

1.02

1.00–1.05

Sex (male)

0.145

0.68

0.40–1.14

Model 2

OPG

 < 0.001

1.08

1.05–1.12

Age

0.128

1.02

1.00–1.04

Sex (male)

0.109

0.64

0.40–1.10

Diabetes

0.654

0.87

0.48–1.58

CVD

0.277

1.44

0.74–2.79

Model 3

OPG

 < 0.001

1.08

1.04–1.12

Age

0.121

1.02

1.00–1.05

Sex (male)

0.089

0.62

0.36–1.08

Diabetes

0.823

0.93

0.50–1.72

CVD

0.371

1.40

0.68–2.85

hsCRP

0.179

1.01

0.99–1.03

Model 4

OPG

0.048

1.04

1.00–1.08

Age

0.005

1.04

1.01–1.07

Sex (male)

0.389

0.78

0.45–1.37

Diabetes

0.816

0.93

0.49–1.74

CVD

0.643

1.18

0.59–2.36

hsCRP

0.029

1.02

1.00–1.04

CKD stage

3 (ref)a

   

4

0.164

0.35

0.08–1.53

5

0.061

2.55

0.96–6.79

  1. Fine and Gray model for mortality (any cause) considering transplant as competing risk.
  2. aStage 3 used as a reference for the analysis.
  3. OPG, osteoprotegerin; CVD, cardiovascular disease; hsCRP, high-sensitivity C-reactive protein; CKD, Chronic Kidney Disease; SHR: subdistribution hazard ratio.
Back to article page